For the quarter ending 2025-06-30, ADAP made $13,677K in revenue. -$30,340K in net income. Net profit margin of -221.83%.
| Income Statement | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 13,677 | 7,285 | 4,450 | 40,901 |
| Selling, general and administrative | 18,485 | 23,282 | 21,995 | 21,277 |
| Research and development | 22,979 | 28,857 | 37,154 | 34,304 |
| Impairment of long-lived assets | - | - | 2,600 | - |
| Cost of goods sold | 2,501 | 879 | 4,091 | - |
| Total operating expenses | 43,965 | 53,018 | 65,840 | 55,581 |
| Interest income, debt securities, available-for-sale, operating | - | - | - | 2,096 |
| (loss)/profit from operations | -30,288 | -45,733 | -61,390 | -14,680 |
| Other income (expense), net | 1,289 | -305 | 435 | -3,093 |
| Interest income | 233 | 910 | 1,649 | - |
| Interest expense | 962 | 1,881 | 857 | 1,109 |
| (loss)/profit before income tax expense | -29,728 | -47,009 | -60,249 | -16,786 |
| Income tax expense | 612 | 575 | 1,110 | 831 |
| Net (loss)/profit attributable to ordinary shareholders | -30,340 | -47,584 | -61,359 | -17,617 |
| Earnings per share, basic | -0.02 | -0.03 | -0.045 | -0.01 |
| Earnings per share, diluted | -0.02 | -0.03 | -0.04 | -0.01 |
| Weighted average shares outstanding, basic | 1,584,522,868 | 1,542,159,622 | -777,167,481 | 1,534,613,977 |
| Weighted average shares outstanding, diluted | 1,584,522,868 | 1,542,159,622 | -789,993,449.5 | 1,534,613,977 |
Adaptimmune Therapeutics PLC (ADAP)
Adaptimmune Therapeutics PLC (ADAP)